Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25027507 | 0.81 | CA1 (0.36) | HTR1ACA1CA2CA7CA9 | |
| SCHEMBL15306032 | 0.81 | KCNH2 (0.33) | HTR1A | |
| SCHEMBL21116508 | 0.80 | HTR1A (0.39) | HTR1AHTR2ACA12CA1CA2 | |
| SCHEMBL25053744 | 0.80 | HTR1A (0.37) | HTR1AHTR2A | |
| SCHEMBL9900837 | 0.79 | NCOA1 (0.40) | ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL9900851 | 0.78 | MAPK1 (0.41) | ALDH1A1PTGS1TDP1 | |
| SCHEMBL29438014 | 0.77 | — | — | |
| SCHEMBL9901103 | 0.77 | — | — | |
| SCHEMBL9901095 | 0.76 | KEAP1 (0.33) | L3MBTL1 | |
| SCHEMBL30794363 | 0.76 | KEAP1 (0.33) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11541052-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-01-03 | — | — | US | disclosed |
| US-11541052-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-01-03 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-20210023084-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2021-01-28 | — | — | US | disclosed |
| US-20210023084-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2021-01-28 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2013083994-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013083994-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | WO | disclosed |
| EP-2513092-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011073114-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110123490-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | HTR1A 677/4885HTR2A 1073/4885CA12 3602/4885 |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | HTR1A 677/4885HTR2A 1073/4885CA12 3602/4885 |
| US-20110123490-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RRM2B, POLR2A, RRM2 | HTR1A 2387/4885HTR2A 3230/4885CA12 4714/4885 |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | HTR1A 670/4885HTR2A 1271/4885CA12 3629/4885 |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | HTR1A 677/4885HTR2A 1073/4885CA12 3602/4885 |
| US-20210023084-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | HTR1A 631/4885HTR2A 871/4885CA12 3934/4885 |
| US-11541052-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | HTR1A 715/4885HTR2A 963/4885CA12 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.